- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2019
- Public Summary Document (PSD) March 2019 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2019 PBAC Meeting - Word
Pembrolizumab – March 2019
Pembrolizumab: Powder for injection 50 mg, Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
Last updated
5 July 2019